The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals is intensifying efforts to translate scientific discovery into tangible therapies for patients with severe retinal diseases.
The company is spotlighting its Northbridge, MA manufacturing facility as a cornerstone in the development and production of these innovative treatments. While technical details remain limited, Eyepoint Pharmaceuticals is guiding viewers to learn more through a related video update. Details are being clarified.
Earlier this year, Eyepoint Pharmaceuticals reported its Q1 2026 financial results and provided an update on its pivotal Phase 3 clinical trial progress. The company has remained focused on advancing therapies for severe retinal diseases. Recent communications have continued to frame development milestones as part of its long-term strategy.